Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
Rhea-AI Summary
Cogent Biosciences (Nasdaq: COGT) has announced its upcoming participation in a fireside chat at the Leerink Healthcare Conference scheduled for March 12, 2025, at 10:00 a.m. ET. The event will be accessible via webcast on the company's Investors & Media webpage, with replay available for 30 days.
Additionally, the company disclosed an inducement equity grant approved by its Compensation Committee on March 4, 2025. Under Nasdaq Listing Rule 5635(c)(4), a new employee received options to purchase 90,000 shares of Cogent common stock. The option features a 10-year term, with a 4-year vesting schedule: 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Positive
- None.
Negative
- None.
WALTHAM, Mass. and BOULDER, Colo., March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Leerink Healthcare Conference on Wednesday, March 12, 2025 at 10:00 a.m. ET.
A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cogent also announced today that the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grant of an “inducement” equity award on March 4, 2025 to one new employee under the company’s 2020 Inducement Plan. The award was approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employee received a nonqualified option to purchase 90,000 shares of Cogent common stock. The option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a 4-year vesting schedule with
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
FAQ
What is the vesting schedule for COGT's new employee stock options granted in March 2025?
How many shares were included in Cogent Biosciences' March 2025 inducement grant?
When is Cogent Biosciences presenting at the Leerink Healthcare Conference 2025?
How long will the replay of COGT's Leerink Conference presentation be available?
